Skip to main content

Combination therapy: synergism among three plant extracts against selected pathogens



The synergism among extracts of Senna alata, Ricinus communis, and Lannea barteri, and their anti-infective activities were investigated. The data collected for the antimicrobial activity of the extracts combinations were interpreted to be one of the following categories: synergy; indifferent; additive; or antagonistic. The interpretation was made based on the fractional inhibitory concentration index (FICI) results. FICI of ≤ 0.5 indicates synergism, > 0.5 to 1 indicates additive effects, > 1 to ≤ 4 indifference, and > 4 is considered to be antagonism.


Compared with the data of the individual extracts, the MIC values of the extract-extract combinations against all strains of the tested microorganisms were significantly lower, ranging from 0.97 to 1.17, 0.97 to 4.69, 0.50 to 1.17, 1.17 to 3.12 and 2.34 to 4.69 mg/mL for Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa, Klebsiella pneumonia and Candida albicans respectively. L. bateri aqueous-S. alata ethanol extracts and S. alata aqueous-R. cummunis ethanol extracts combinations showed a synergy effect against all the test microorganisms. The other combinations exhibited at least one additive effect. Neither antagonism nor indifference activity was observed. This study validates the relevance of combining these plants in treating infections by traditional medicine practitioners.

Peer Review reports


Advances in the treatment and prevention of disease rely on novel therapeutics, which are based on innovative drug targets. Scientists dedicate a significant amount of time and money to exploring the new potential targets essential to continuing medical advancements [1].

Antibiotics have become increasingly less active against certain ailments not only because they create noxious responses but also due to the upsurge of drug-resistant microorganisms [2, 3].

Traditional herbal medicines are mostly prepared as a combination therapy that has been used since therapeutic was first practiced [18]. Combination therapy is reported as helpful and useful for patients with serious infections caused by drug-resistant pathogens. The purpose of synergistic therapeutic effect is attributed to dose and toxicity reduction and further minimizing the induction of drug resistance [4].

Previous work conducted in our laboratory has already documented the in vitro activities of the extracts of Senna alata, Ricinus cummunis and Lannea barteri acting alone against some clinically isolated bacterial and fungal species [5]. The goal of this research was to investigate possible extract-extract interaction of the plants as a potential combination therapy against selected clinically isolated pathogenic microorganisms.

Materials and methods

Plant materials

The plant material of S. alata, R. communis and L. barteri were collected from Navrongo (10° 53′ 5.00′′ N, 1° 05′ 25.00′′ W), Ghana, as previously described [6]. The plant was identified and authenticated by a plant taxonomist at the herbarium of Ghana Herbaria, Northern Savanna Biodiversity; Savanna Herbarium. The voucher specimens with numbers of SH 71 (S. alata), SH 720 (R. cummunis) and SH 790 (L. Barteri) were deposited in the herbarium.

Preparation of plant extracts

Leaf of S. alata, leaf of R. cummunis, and stem bark of L. barteri were thoroughly washed with distilled water, and air dried under shade for two weeks. Each plant sample was pulverized using blender. One hundred grams of each sample was percolated with 1L of (ethanol and water) at room temperature with frequent agitation for 48 h. They were then filtered using Whitman No 42 filter paper, concentrated using rotary evaporator (Heidoph 4001 Efficient) on water bath at 70 °C for the aqueous and 50 °C for the ethanol [6] to obtain a semi-solid and solid residue respectively. A stock solution of 400 mg/mL in dimethyl sulfoxide (DMSO, 99.99%) was prepared from each extract. Extracts were labeled as LBA (L. barteri aqueous extract), LBE (L. barteri ethanol extract), SAA (S. alata aqueous extract), SAE (S. alata ethanol extract), RCA (R. cummunis aqueous extract) and RCE (R. cummunis ethanol extract). Two-fold dilution was used to prepare varying concentrations (200, 100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 0.78 mg/mL) to determine the minimum inhibition concentration (MIC) of each extract alone. For the combination study, the same volume (1:1) of two different extracts (further diluted by two-fold from their respective MICs) were combined. The extracts were stored at ≤ 4 °C until further use.

Pathogenic microorganisms

Clinical isolates of Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae and Candida albicans were obtained from incision-type wounds at the Microbiology Department of the Tamale Teaching Hospital, Tamale Ghana.

Antimicrobial bioassay

The MIC of the extracts in combination was determined using similar procedure already described by Donkor et al. and Suurbaar et al. [5, 6]. Briefly, overnight cultured bacteria were suspended in 5 mL sterile nutrient broth (NB) and incubated at 37 °C for 2–4 h to achieve a turbidity equivalent to 0.5 McFarland standard (1.0 × 108 cfu/mL). The fungal spores were washed from the surface of agar plates with sterile 0.85% (w/v) saline containing 0.1% Tween 80 (v/v). The spore suspension was adjusted with sterile saline to a concentration of approximately 1.0 × 107 cfu/mL. Sterile NB (2 mL) was inoculated with 0.1 mL of test micororganism in a sterile test tube. The same volume (1:1) of two different extracts (further diluted by two-fold from their respective MICs) were combined in a permutation fashion. The combined extract, 1 mL each, was added to sterile test tubes containing the inocula. The tubes were incubated aerobically at 37 °C for 24 h for bacteria and 48 h for the fungus. The MIC for a combination was calculated as the minimum of the sum of a pair showing no growth. Amoxicillin (2.50 µg/mL) and Fluconazole (1.50 µg/mL) were used as the positive controls for bacteria and fungus respectively.

Synergy analysis

The extract-extract interactions were analyzed using the fractional inhibition concentration index (FICI) (or ΣFIC) as shown in Eq. 1.

$$FICI = \sum FIC =\, \frac{MIC \,of \,extract \,A \,in \,combination}{{MIC \,of \,extract \,A \,alone}} + \frac{MIC \,of \,extract \,B \,in \,combination}{{MIC \,of \,extract \,B \,alone}}$$

The FICI is based on the Loewe additivity zero interaction theory [7,8,9]. A FICI of ≤ 0.5 indicates synergism, > 0.5 to 1 indicates additive effects, > 1 to ≤ 4 indifference, and > 4 is considered to be antagonism [10, 11].


In vitro, extract-extract interactions between the selected medicinal plants on the test clinical microbial isolates were conducted in the current work. Different extracts from the same plant were not considered. The MICs of the extracts acting alone were reported in a previous study conducted in our laboratory [5, 6]. It was observed that MICs ranged between 3.13 and 25.00 mg/mL. In the current work, the MICs of the extracts in combination are shown in Table 1 (and Additional file 1: Table S1). It was observed that the combined extracts gave considerably lower MICs against the entire tested microorganisms than the extracts alone. The MICs of the extracts in combination were species-specific, ranging from 0.97 to 1.17, 0.97 to 4.69, 0.50 to 1.17, 1.17 to 3.12 and 2.34 to 4.69 mg/mL for E. coli, S. aureus, P. aeruginosa, K. pneumoniae and C. albicans respectively. The lower MICs could be attributed to the enhanced inhibitory activities of the extracts in a combined form. Synergistic studies between extract-extract combinations of plants are limited in the literature, making a comparison of results from different studies exceptionally challenging. Obuekwe et al. [12] reported that different zones of inhibition were measured using diverse extract combinations and indicated that E. coli exhibited a maximum zone concerning the extracts combination of Bryophyllum pinnatum and Ocimum gratissimum in 30 mg/mL concentration (27.25 ± 1.70 mm). Nonetheless, the utmost zone of inhibition was detected with S. aureus in 10 mg/ml concentration regarding ethyl acetate extracts of Ocimum gratissimum and Ficus exasperata (31.75 ± 3.07 mm) [12]. Related research reports indicated that drug interactions between known antibiotics and plant extracts have potential benefits [4].

Table 1 Representative MIC (mg/mL) and FICI of L. barteri, S. alata and R. communis extracts in combination

The combination of more than one category of drug constituent is regularly used in medicine. A particular strategy does not constantly enrich its particular pharmacological effect; combinations comprising two or more components can afford additive, synergistic, or antagonistic effects [19]. Records show that if treatment using a drug combination gives a better pharmacological effect than monotherapy in clinical trials, it can be concluded that it has a synergistic effect [13]. Kumar et al. [14] reported the synergistic activity of oxytetracycline with methanol extract of Thespesia populnea. They observed that the MICs of the combination on 12 different Gram-positive and Gram-negative bacteria were around 62.5–1000 µg/mL.

In the current study, it was observed that only LBA + SAE and SAA + RCE combinations showed a synergy effect on all the test microorganisms. However, the other combinations exhibited a synergy effect on at least one microorganism, though some showed an additive effect. For example, LBA + SAA had a synergy effect on all microorganisms except on E. coli which indicated additivity. Furthermore, none of the combinations produced an antagonistic or indifference mechanism (Table 1, Additional file 1: Table S1). According to Caesar and Cech [15], combination therapy is more likely to prevent disease resistance than single pure active constituents. For instance, it is reported that purified artemisinin as monotherapy is more likely to develop resistance in Plasmodium parasites than whole-plant Artemesia annua extracts or refined fractions [16]. It is on this score that the World Health Organization (WHO) has promoted the use of artemisinin combination therapies (ACTs) in the treatment of Plasmodium falciparum malaria to enhance efficacy and reduce resistance. Another renowned antimicrobial agent exhibiting a significant synergistic effect in combination is Co-amoxiclav [20].

In a combined therapy, each bioactive compound exerts a synergistic or an additive effect, thus improving therapeutic efficacy while reducing dose and toxicity. Additionally, an outcome of synergism resulting from combination therapy is to minimize or delay the emergence of resistance by the pathogenic organism to the individual components of the combination [4, 17]. The synergy and additive effects exhibited by the extract-extract interactions in the current work could be attributed to the different phyto-compounds in the individual extracts [5, 6] acting in concert, each introducing a different mechanism to inhibit or kill the microbial growth.

Phytochemical screening showed the presence of most or all of the following: tannins, saponins, polyuronoids, reducing sugars, terpenoids, flavonoids and alkaloids in both aqueous and ethanolic extracts of S. alata, L. barteri and R. communis. Alkaloids are reported to have cytotoxicity properties [21]. Phenanthroindolizidine plant alkaloids are reported to inhibit the activity of dihydrofolate reductase, thereby inhibiting nucleic acid synthesis [22]. Additionally, alkaloids, terpenoids, and phenolic compounds are known to inhibit bacterial and fungal infections [23]. Saponins are reported to interfere with cell replication, including cancer cells [24]. Tannins are linked with complexing with proteins through both covalent and non-covalent interactions, and capable of complexing with polysaccharides [25]. Synergy might have resulted from the targeting of multiple pathways, which may include substrates, enzymes, metabolites, ion channels, ribosomes, and signal cascades [26].


Traditional medicines have a wide-ranging treatment concept, and have the advantages of multiple targets, links, and approaches. The current findings validate the relevance of combining S. alata, R. communis and L. barteri in treating infections by traditional health practitioners and the need for comprehensive studies in vivo.


This work was carried out on a fixed ratio of 1:1 instead of considering various ratios. This could be a limitation because combination effects may occur over a vast range of concentrations.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author upon reasonable request.




C. albicans :

Candida albicans


Colony forming unit

E. coli :

Escherichia coli


Fractional inhibition concentration index

K. pneumoniae :

Klebsiella pneumoniae

L. barteri :

Lannea barteri


Lannea barteri aqueous extract


Lannea barteri ethanol extract


Minimum inhibition concentration

P. aeruginosa :

Pseudomonas aeruginosa

R. communis :

Ricinus communis


Ricinus communis aqueous extract


Ricinus communis ethanol extract



S. alata :

Senna alata


Senna alata aqueous extract


Senna alata ethanol extract

S. aureus :

Staphylococcus aureus


  1. Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today. 2011;16(23–24):1037–43.

    Article  CAS  PubMed  Google Scholar 

  2. Donkor AM, Donkor MN, Kuubabongnaa N. Evaluation of anti-infective potencies of formulated aloin A ointment and aloin A isolated from Aloe barbadensis Miller. BMC Chem. 2020;14(1):1–8.

    Article  CAS  Google Scholar 

  3. Chanda S, Rakholiya K. Combination therapy : synergism between natural plant extracts and antibiotics against infectious diseases. Formatex. 2011;2011:520–9.

    Google Scholar 

  4. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–6.

    Article  CAS  PubMed  Google Scholar 

  5. Donkor AM, Mosobil R, Suurbaar J. In Vitro bacteriostatic and bactericidal activities of Senna alata, Ricinus communis and Lannea barteri extracts against wound and skin disease causing bacteria. J Anal Pharm Res. 2016;3(1):1–6.

    Google Scholar 

  6. Suurbaar J, Mosobil R, Donkor AM. Antibacterial and antifungal activities and phytochemical profile of leaf extract from different extractants of Ricinus communis against selected pathogens. BMC Res Notes. 2017;10(1):1–6.

    Article  Google Scholar 

  7. White RL, Burgess DS, Manduru M, Bosso JA. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother. 1996;40(8):1914–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Jenkins SG, Schuetz AN. Current concepts in laboratory testing to guide antimicrobial therapy. Mayo Clin Proc. 2012;87(3):290–308.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Berenbaum MC. What is synergy? Pharmacol Rev. 1989;41(2):93–141.

    CAS  PubMed  Google Scholar 

  10. Isenberg HD. synergism testing broth microdilution checkerboard and broth macrodilution methods. In: Isenberg HD, editor. Clinical microbiology procedures handbook. 2nd ed. Washington DC: American society microbiology; 1992.

    Google Scholar 

  11. Noor S. Synergistic effect of the methanolic extract of lemongrass and some antibiotics to treat urinary tract bacteria. J Biosci Med. 2016;04(11):48–58.

    CAS  Google Scholar 

  12. Obuekwe IS, Okoyomo EP, Anka US. Effect of plant extract combinations on some bacterial pathogens. J Appl Sci Environ Manag. 2020;24(4):627–32.

    Google Scholar 

  13. Setiawan PYB, Kertia N, Nurrochmad A, Wahyuono S. Curcumin in combination: review of synergistic effects and mechanisms in the treatment of inflammation. J Appl Pharm Sci. 2021;11(2):001–11.

    CAS  Google Scholar 

  14. Kumar AS, Venkateshwaran K, Vanitha J, Saravanan VS, Ganesh M, Vasudevan M, et al. Synergistic activity of methanolic extract of Thespesia populnea (Malvaceae) flowers with oxytetracycline. Bangladesh J Pharmacol. 2009;4(1):13–6.

    Google Scholar 

  15. Caesar K, Cech NB. Synergy and antagonism in natural product extracts: when 1 + 1 does not equal 2. Nat Prod Rep. 2019;36(6):869–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Rasoanaivo P, Wright CW, Willcox ML, Gilbert B. Whole plant extracts versus single compounds for the treatment of malaria: synergy and positive interactions. Malar J. 2011;10(Suppl 1):S4.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Mohd Ridzuan MRU, Noor Rain A, Khozirah S, Zakiah I. Antimalarial properties of Goniothalamin in combination with chloroquine against Plasmodium yoelii and Plasmodium berghei growth in mice. Trop Biomed. 2006;23(2):140–6.

    CAS  PubMed  Google Scholar 

  18. Mason E, Routledge PA. Combination therapy of diseases: General concepts. Cambridge: Cambridge University Press; 2005.

    Google Scholar 

  19. Vaou N, Stavropoulou E, Voidarou C, Tsakris Z, Rozos G, Tsigalou C, Bezirtzoglou E. Interactions between medical plant-derived bioactive compounds: focus on antimicrobial combination effects. Antibiotics. 2022;11(8):1014.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Knight M, Chiocchia V, Partlett C, Rivero-Arias O, Hua X, Bowler U, Gray J, Gray S, Hinshaw K, Khunda A, Moore P. Intravenous co-amoxiclav to prevent infection after operative vaginal delivery: the ANODE RCT. Health Technol Assess. 2019;23(54):1.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Nobori T, Miurak K, Wu DJ, Takabayashik LA, Carson DA. Deletion of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nat. 1994;368(6473):753–6.

    Article  CAS  Google Scholar 

  22. Rao KN, Venkatachalam SR. Inhibition of dihydrofolate reductase and cell growth activity by the phenanthroindolizidine alkaloids pergularinine and tylophorinidine: the in vitro cytotoxicity of these plant alkaloids and their potential as antimicrobial and anticancer agents. Toxicol In Vitro. 2000;14(1):53–9.

    Article  CAS  PubMed  Google Scholar 

  23. Mishra A, Sharma AK, Kumar S, Saxena AK, Pandey AK. Bauhinia variegata leaf extracts exhibit considerable antibacterial, antioxidant, and anticancer activities. BioMed Res Int. 2013.

    Article  PubMed  PubMed Central  Google Scholar 

  24. de Mendonça IC, Porto IC, do Nascimento TG, de Souza NS, Oliveira JM, Arruda RE, Mousinho KC, dos Santos AF, Basílio-Júnior ID, Parolia A, Barreto FS. Brazilian red propolis: phytochemical screening, antioxidant activity and effect against cancer cells. BMC Complement Altern Med. 2015;15(1):1–2.

    Article  Google Scholar 

  25. Othman L, Sleiman A, Abdel-Massih RM. Antimicrobial activity of polyphenols and alkaloids in middle eastern plants. Front Microbiol. 2019;10:911.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Wagner H, Ulrich-Merzenich G. Synergy research: approaching a new generation of phytopharmaceuticals. Phytomedicine. 2009;16(2–3):97–110.

    Article  CAS  PubMed  Google Scholar 

Download references


The authors would like to acknowledge the management and staff of the School of Chemical and Biochemical Sciences, C. K. Tedam University of Technology and Applied Sciences, Navrongo, Ghana, for the use of laboratories and other facilities.


This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations



AMD, MND and RM conceived and designed the study; RM collected the plant samples and performed the experiments; AMD, MND performed statistical/data analysis; AMD, MND and RM contributed equally in drafting and writing the paper. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Martin Ntiamoah Donkor or Addai-Mensah Donkor.

Ethics declarations

Ethics approval and consent to participate

The plant materials were collected from the wild in accordance with Biodiversity Conservation and Sustainable Harvesting under the Policy Guidelines on Traditional Medicine, Ministry of Health, Ghana. Permission was sought from the owner of the property on which the plants were found, and same was granted before the collection.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1: Table S1.

MICand FICI of Lannea barteri, Senna alata and Ricinus communis extracts in combination.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Donkor, M.N., Donkor, AM. & Mosobil, R. Combination therapy: synergism among three plant extracts against selected pathogens. BMC Res Notes 16, 83 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: